Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) [Phase 3]

View source ↗

Summary

A Phase 3 study (MK-3475-426/KEYNOTE-426) evaluating pembrolizumab in combination with axitinib versus sunitinib monotherapy in renal cell carcinoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• KEYTRUDA (PEMBROLIZUMAB)
• Sutent (sunitinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2019-11-08